Telavant’s first investigational product, RVT-3101, is a fully human monoclonal antibody targeting TL1A. In nonclinical studies and in clinical trials conducted to date, RVT-3101 has been observed to neutralize TL1A signaling. TL1A has been shown to modulate the location and severity of inflammation and fibrosis by stimulating TH1 and TH17 pathways, in addition to activating fibroblasts. We are developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn’s disease, including for patients with a prospectively defined biomarker who may benefit from a precision approach utilizing RVT-3101.

Ulcerative Colitis
Phase 3
Crohn's Disease
Phase 2
Next-generation anti-TL1A*
Inflammatory/Fibrotic Diseases
Phase 1

* Telavant has an exclusive option to collaborate with Pfizer on global development of the p40/TL1A directed bispecific antibody PF-07261271, sharing costs 50/50, and to co-commercialize worldwide, exercisable prior to Phase 2 start

Expanded Access Policy